Company Overview and News

 
An evening walk down Dalal Street | Pain continues on market, Sensex sheds 169 pts, Nifty gives up 11,250; midcaps fall

2018-09-19 moneycontrol
Equity benchmarks ended a volatile trading day on a negative note as consumer names as well as banks weighed. The Nifty ended below 11,250-mark, while the Sensex shed a little over 160 points. Rupee heading towards its low points also dented sentiment on the market.
524715 500325 INDUSINDBK RELIANCE 532978 BHRQY 533278 532454 BAJAJFINSV 532187 RIGD SUNPHARMA BHARTIARTL CLNDY COALINDIA RLNIY

 
Bajaj Finserv Limited - Allotment of Securities

2018-09-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BAJAJFINSV 532978

 
Stocks slump on trade war

2018-09-10 thehindubusinessline
The escalating tariff war between the US and China had a ripple effect on Indian financial markets on Monday, roiling equity and forex markets alike.
AXB IDKQY HCTHY 532978 532215 AXBKY 535789 IBULHSGFIN AXBA BAJAJFINSV BAJFINANCE ZEEEY AXISBANK HCLTECH 505537 532281 BJJQY ZEEL 500034

 
An evening walk down Dalal Street | Global cues, banks and metals fuel rally on D-Street; Nifty ends just below 11,700

2018-08-27 moneycontrol
What a cracker of a Monday that was for the market! Bulls had it their way throughout the session, gaining with every passing hour. Benchmarks ended the day at record high levels. The Nifty managed to clock 11,700-mark as well.
500325 SUNDARMFIN 570002 RELIANCE FRL 532978 BHRQY SRTRANSFIN 511218 532454 BAJAJFINSV LICHSGFIN FRLDVR RIGD SRRQY 523574 LHFLY BHARTIARTL 590071 500253 RLNIY SNDMY

 
Treat Your Siblings to the Best Gifts this Year Using EMI Finance

2018-08-23 freepressjournal.in
Take the time to let your siblings know how much you love them this Raksha Bandhan. What better way to show you care than by gifting your sister or brother a laptop, latest fashion apparel and accessories or a high-end smartphone? Besides, you need not worry about your salary being late or dipping into your savings. You can shop without exceeding your budget by shopping from the Bajaj Finserv EMI Network.
BAJAJFINSV 532978

 
Samsung launches Galaxy Note 9 in India; price, specs and where to buy

2018-08-22 moneycontrol
South Korean tech giant Samsung launched its latest and its most powerful flagship smartphone yet -- the Galaxy Note 9 -- in India on Wednesday, August 22. The much-anticipated device was unveiled globally earlier this month.
BAJAJFINSV 532978

 
Check out top 10 stocks which moved the most last week; HDIL registers 50% gain

2018-08-19 moneycontrol
The market ended a truncated week on a good note, as benchmark indices closed with strong gains. The Nifty ended the day at a record closing high, while the Sensex ended higher by almost 300 points. Having said that, it failed to hold 38,000-mark.
PAGEIND 500449 UBL 532978 533155 TTNQY JUBLFOOD 532478 FILATEX RAIN BIRLAPREC 532540 JBLWY 509488 526227 522105 PGDQY EXIDEIND 517354 HVLQY GRAPHITE 532827 500339 UBHOLDINGS UNBWY HOCL EXQDY BAJAJFINSV BATAINDIA HAVELLS TCS 500086 507458 500043

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...